Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.390 -0.120 (-4.78%)
Streaming Delayed Price Updated: 10:22 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,660
Open 2.500
Bid (Size) 2.390 (100)
Ask (Size) 2.400 (100)
Prev. Close 2.510
Today's Range 2.380 - 2.510
52wk Range 0.8551 - 3.050
Shares Outstanding 40,501,258
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks have an unusual volume in today's session ↗
Via Chartmill
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill

Performance

YTD
+18.3%
+18.3%
1 Month
+28.5%
+28.5%
3 Month
+51.3%
+51.3%
6 Month
+67.1%
+67.1%
1 Year
+64.8%
+64.8%

More News

Read More
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
Acumen Pharmaceuticals's Earnings: A Preview ↗
Via Benzinga
News headline image
A Preview Of Acumen Pharmaceuticals's Earnings ↗
Via Benzinga
News headline image
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗
Via Chartmill
Topics Earnings
News headline image
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Preview: Acumen Pharmaceuticals's Earnings ↗
Via Benzinga
News headline image
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 12, 2025 ↗
Via Benzinga
News headline image
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 13, 2025 ↗
Via Benzinga

Frequently Asked Questions

Is Acumen Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Acumen Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Acumen Pharmaceuticals, Inc. - Common Stock trade on?
Acumen Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock is ABOS on the Nasdaq Stock Market
What is the current price of Acumen Pharmaceuticals, Inc. - Common Stock?
The current price of Acumen Pharmaceuticals, Inc. - Common Stock is 2.390
When was Acumen Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Acumen Pharmaceuticals, Inc. - Common Stock was at 02/17/26 10:22 AM ET
What is the market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock is 96.80M
How many shares of Acumen Pharmaceuticals, Inc. - Common Stock are outstanding?
Acumen Pharmaceuticals, Inc. - Common Stock has 97M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.